Last checked at 13 Sep 2016 09:25
Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Awards
London, UK, 13th September 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that, following approval at the AGM on 4th August 2016, it has granted awards in the form of options over ordinary shares in the capital of the Company ("Award Shares") to the following executives under its Long Term Incentive Plan ("LTIP").
Carl Sterritt: Director 92,767
Richard Jones: Director 67,610
Paul Steckler PDMR 58,176
Angela Hildreth PDMR 34,591
In total awards have now been granted over 2,026,725 shares under the LTIP. The exercise price per Award Share is 1.5 pence and awards are exercisable between February 2019 and February 2026, subject to applicable performance conditions having been satisfied. The grant of awards is part of the Company's long-term incentive arrangements designed to directly align the interest of the shareholders and executives.
The Company's LTIP was adopted by the Board on 12th February 2016. The LTIP provides for awards of ordinary shares to be made to eligible employees. The arrangements are described more fully in the Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).
-Ends-
For further information please contact:
Shield Therapeutics plc | +44 (0)191 511 8507 |
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer |
|
|
|
Nominated Adviser and Sole Broker Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah | +44 (0)20 3100 2222 |
|
|
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys |
|
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities/person closely associated
| |
a) | Name
| Carl Sterritt: Director / PDMR Richard Jones: Director / PDMR Paul Steckler PDMR Angela Hildreth PDMR
|
2 | Reason for the notification
| |
a) | Position/status
| All PDMRs of Shield Therapeutics |
b) | Initial notification/ Amendment
| Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
a) | Name
| Shield Therapeutics plc |
b) | LEI
| n/a |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
a) | Description of the financial instrument, type of instrument
Identification code
| Option over ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 |
b) | Nature of the transaction
| Grant of Options over ordinary shares in accordance with the Company's Long Term Incentive Plan |
c) | Price(s) and volume(s)
| Exercise price: 1.5p
Volumes: Carl Sterritt: 92,767 Richard Jones: 67,610 Paul Steckler 58,176 Angela Hildreth 34,591
|
d) | Aggregated information
- Aggregated volume
- Price
|
253,144
Exercise price: 1.5p |
e) | Date of the transaction
| 12 September 2016 |
f) | Place of the transaction
| Outside a trading venue |
Name of authorised official of issuer responsible for making notification.
Richard Jones
CFO and Company Secretary to Shield Therapeutics plc